57 / 61
Corral,et al M. IASLC WCLC 2017
Table 3. ORR to nintedanib/docetaxel (N=11)
Nintedanib + docetaxel
ORR
36.5%
CR
0
PR
4 (36.5%)
SD
5 (45.5%)
PD
2 (18.2%)
DCR
82%
ORR
: overall response rate;
CR
: complete response;
PR
: partial response;
SD
: stable disease;
PD
: progressive disease;
DCR
: disease control rate.
Nintedanib/docetaxel efficacy in advanced lung adenocarcinoma treated with
1L chemotherapy / 2L immunotherapy in nintedanib NPU program